Ullamari Pesonen

Ullamari Pesonen

Auto-generated profile, based on publicly available information

Ullamari Pesonen

Orion Corporation, Orion Pharma, Orionintie 1A, 02200 Espoo, Finland

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MKMatti K. Karvonen
Matti K. Karvonen
UPUllamari Pesonen
Ullamari Pesonen
MKMarkku Koulu
Markku Koulu
LNLeo Niskanen
Leo Niskanen
MLMarkku Laakso
Markku Laakso
MUMatti I.J. Uusitupa
Matti I.J. Uusitupa

1 June 2009 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
MHMika M. Hirvonen
Mika M. Hirvonen
VLVille Lumme
Ville Lumme
JHJussi Hirvonen
Jussi Hirvonen
UPUllamari Pesonen
Ullamari Pesonen
KNKjell Någren
Kjell Någren
JHJarmo Hietala
Jarmo Hietala

17 May 2002 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
MHMoonseong Heo
Moonseong Heo
RLRl Leibel
Rl Leibel
KFKr Fontaine
Kr Fontaine
BBBb Boyer
Bb Boyer
WCWk Chung
Wk Chung
DADb Allison
Db Allison

1 July 2015 in Pain
Verified
Journal Article
Closed access
PLPauliina Lindholm
Pauliina Lindholm
SLSalla Lamusuo
Salla Lamusuo
TTTero Taiminen
Tero Taiminen
UPUllamari Pesonen
Ullamari Pesonen
ALAri Lahti
Ari Lahti
SJSatu Jääskeläinen
Satu Jääskeläinen
High-frequency repetitive transcranial magnetic stimulation (rTMS) of the motor cortex has analgesic effect; however, the efficacy of other cortical targets and the mode of action remain unclear. We examined the effects of rTMS in neuropathic orofacial pain, and compared 2 cortical targets against placebo. Furthermore, as dopaminergic mechanisms modulate pain responses, we assessed the influence of the functional DRD2 gene polymorphism (957C>T) and the catechol-O-methyltransferase (COMT) Val158Met polymorphism on the analgesic effect of rTMS. Sixteen patients with chronic drug-resistant neuropathic orofacial pain participated in this randomized, placebo-controlled, crossover study. Navigated high-frequency rTMS was given to the sensorimotor (S1/M1) and the right secondary somatosensory (S2) cortices. All subjects were genotyped for the DRD2 957C>T and COMT Val158Met polymorphisms. Pain, mood, and quality of life were monitored throughout the study. The numerical rating scale pain scores were significantly lower after the S2 stimulation than after the S1/M1 (P = 0.0071) or the sham (P = 0.0187) stimulations. The Brief Pain Inventory scores were also lower 3 to 5 days after the S2 stimulation than those at pretreatment baseline (P = 0.0127 for the intensity of pain and P = 0.0074 for the interference of pain) or after the S1/M1 (P = 0.001 and P = 0.0001) and sham (P = 0.0491 and P = 0.0359) stimulations. No correlations were found between the genetic polymorphisms and the analgesic effect in the present small clinical sample. The right S2 cortex is a promising new target for the treatment of neuropathic orofacial pain with high-frequency rTMS.

1 November 2001 in Atherosclerosis
Verified
Journal Article
Closed access
MKMatti K Karvonen
Matti K Karvonen
VVVeli-Pekka Valkonen
Veli-Pekka Valkonen
TLTimo Lakka
Timo Lakka
RSRiitta Salonen
Riitta Salonen
MKMarkku Koulu
Markku Koulu
JSJukka T Salonen
Jukka T Salonen

15 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHenriikka Salomäki
Henriikka Salomäki
LVLaura H. Vähätalo
Laura H. Vähätalo
KLKirsti Laurila
Kirsti Laurila
NJNorma T. Jäppinen
Norma T. Jäppinen
APAnna-Maija Penttinen
Anna-Maija Penttinen
MKMarkku Koulu
Markku Koulu
The antidiabetic drug metformin is currently used prior and during pregnancy for polycystic ovary syndrome, as well as during gestational diabetes mellitus. We investigated the effects of prenatal metformin exposure on the metabolic phenotype of the offspring during adulthood in mice. Metformin (300 mg/kg) or vehicle was administered orally to dams on regular diet from the embryonic day E0.5 to E17.5. Gene expression profiles in liver and brain were analysed from 4-day old offspring by microarray. Body weight development and several metabolic parameters of offspring were monitored both during regular diet (RD-phase) and high fat diet (HFD-phase). At the end of the study, two doses of metformin or vehicle were given acutely to mice at the age of 20 weeks, and Insig-1 and GLUT4 mRNA expressions in liver and fat tissue were analysed using qRT-PCR. Metformin exposed fetuses were lighter at E18.5. There was no effect of metformin on the maternal body weight development or food intake. Metformin exposed offspring gained more body weight and mesenteric fat during the HFD-phase. The male offspring also had impaired glucose tolerance and elevated fasting glucose during the HFD-phase. Moreover, the expression of GLUT4 mRNA was down-regulated in epididymal fat in male offspring prenatally exposed to metformin. Based on the microarray and subsequent qRT-PCR analyses, the expression of Insig-1 was changed in the liver of neonatal mice exposed to metformin prenatally. Furthermore, metformin up-regulated the expression of Insig-1 later in development. Gene set enrichment analysis based on preliminary microarray data identified several differentially enriched pathways both in control and metformin exposed mice. The present study shows that prenatal metformin exposure causes long-term programming effects on the metabolic phenotype during high fat diet in mice. This should be taken into consideration when using metformin as a therapeutic agent during pregnancy.